EGFR and lip and oral cavity carcinoma: In agreement with previous studies,45 we found herein that dasatinib at 10 μM largely inhibits the phosphorylation of EGFR, PKB and ERK‐1/2 in both YD‐38 and HSC‐3 cells, further advocating dasatinib's multi‐targeted tyrosine kinase inhibition in both non‐tumorigenic and tumorigenic human oral cancer cells.